Clinical research
With the Pfizer-BioNTech and Moderna COVID-19 vaccines currently authorized in the U.S. and being distributed and dosed, some of the attention is shifting to Johnson & Johnson’s efforts for its one-shot vaccine.
GSK has discontinued a Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody aimed at treating ulcerative colitis licensed from Immutep Limited following an interim assessment of an Independent Data Monitoring Committee.
California-based Avidity Biosciences has a goal of disrupting the way RNA-based therapies are delivered to patients through its Antibody-Oligonucleotide Conjugates (AOCs) platform.
Protecting the most vulnerable, Eli Lilly’s bamlanivimab significantly reduced COVID-19 risk for nursing home residents in a Phase III trial.
The decision was made based on an Independent Data Monitoring Committee recommendation which indicated the study was unlikely to meet its specified primary efficacy endpoint of progression-free survival.
NEUVOGEN’s official strategy revolves around covering the entire immune system so that the tumor cannot perform an “immune escape”. Past immune priming efforts have fallen short because they focus on only a handful of important targets that some tumor cells may not express, thereby allowing them to escape the therapy’s boundaries.
An investigational oral MK2 inhibitor from Aclaris Therapeutics was safe and associated with promising reductions in inflammatory markers in a 12-week, Phase II a study of patients with moderate to severe rheumatoid arthritis.
VP-102, which has the potential to be the first product approved by the FDA for the treatment of molluscum contagiosum, contains a GMP-controlled formulation of cantharidin (0.7% w/v), which is delivered via a single-use applicator that allows for precise topic dosing and targeted administration.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
Being studied for GAD, OCD, AD and spinocerebellar ataxia, Biohaven’s troriluzole has now struck out in 3 late-stage studies.
PRESS RELEASES